巨星醫療控股(02393.HK):正主動與新優先票據的主要持有人對話
格隆匯1月3日丨巨星醫療控股(02393.HK)發佈公吿,有關公司所發行本金額約為1.98億美元於2026年到期的9.5%優先票據(“新優先票據”)。自2020年COVID-19疫情爆發以來,集團的業務表現因而受到沉重打擊。監於營運及現金流產生受干擾,集團繼續面對流動資金方面的重大限制。
根據規管新優先票據的契約,公司於2022年12月30日或之前到期贖回新優先票據原本金額的5%。於該公吿日期,公司並無贖回任何新優先票據。此外,新優先票據的利息已於2022年12月30日到期應付。根據規管新優先票據的契約,公司有30天的寬限期支付利息。於該公吿日期,公司預期於寬限期屆滿前不會有流動資金支付有關利息。
公司正在評估其流動資金狀況、整體業務營運及經營環境,並正積極探求各種紓解流動資金憂慮的潛在解決方法。公司正主動與新優先票據的主要持有人對話,以期探求及循潛在途徑解決流動資金問題並達成共識方案,以最佳方式保障其所有持份者的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.